Dollars for Profs
Dig Into University Researchers' Outside Income and Conflicts of Interest
Published Dec. 6, 2019
This database was last updated in December 2019 and should only be used as a historical snapshot. There may be new or amended records not reflected here.
Conflict of Interest
Institutions must file significant disclosures to the National Institutes of Health if they determine financial relationships could affect the design, conduct or reporting of the NIH-funded research. The NIH provided us with their entire financial conflict of interest database, with filings from 2012 through 2019.
Should you be removed from our database? Contact us at [email protected]. Read more below.
Konstantin Ichtchenko
Tufts University Boston, Department: Veterinary Sciences
Should you be removed from our database? Contact us at [email protected]. Read more below.
CytoDel, LLC
Equity Interest - Non-publicly traded entity ( e.g., stock, stock option, or other ownership interest)
Dr. Konstantin Ichtchenko (the Principal-Investigator in this study) is a co-founder of CytoDel, LLC (“CytoDel”) and a co-inventor of its technology (for which no royalties have been paid). CytoDel was founded to commercialize technology based on recombinant derivatives of botulinum neurotoxin used to improve therapeutics, cosmetic indications, and drug delivery directly to neurons. Dr. Ichtchenko’s research appears to be related to the technology licensed to CytoDel.
A platform for therapeutic agents that promote rapid recovery from botulism
Public Health Relevance: Botulinum neurotoxin is an extremely dangerous, CDC Category A biodefense threat that is widely available, easily produced, exceedingly toxic and for which no antidote is available. Furthermore, at least seven different toxin types exist, each constituting of different drug targets and thus requiring distinct, challenging and expensive small molecule drug development programs. In contrast, the innovative new platform for biomolecule therapeutics that we propose to develop has the potential to quickly lead to commercially viable antidotes for all BoNT serotypes. Relevance. Botulinum neurotoxin is an extremely dangerous, CDC Category A biodefense threat that is widely available, easily produced, exceedingly toxic and for which no antidote is available. Furthermore, at least seven different toxin types exist, each constituting different drug targets and thus requiring distinct, challenging and expensive small molecule drug development programs. In contrast, the innovative new platform for biomolecule therapeutics that we propose to develop has the potential to quickly lead to commercially viable antidotes for all BoNT serotypes.
Filed on February 15, 2017.
Tell us what you know about Konstantin Ichtchenko's disclosure
We're still reporting about conflicts of interest. Is there something you'd like to tell us about this disclosure?
Other search results for: “Konstantin Ichtchenko”
| Name | Institution | Type | Company | Disclosed Value |
|---|---|---|---|---|
| Konstantin Ichtchenko | New York University School of Medicine | Conflict of Interest | CytoDel, LLC | $20,000 - $39,999 |
| Konstantin Ichtchenko | New York University School of Medicine | Conflict of Interest | CytoDel, LLC | Value cannot be readily determined |
| Konstantin Ichtchenko | New York University School of Medicine | Conflict of Interest | CytoDel, LLC | $20,000 - $39,999 |
| Konstantin Ichtchenko | New York University School of Medicine | Conflict of Interest | CytoDel, LLC | $200,000 - $249,999 |
Notes: When a more specific filing date is not available for an individual financial disclosure or conflict of interest form, we use the year the form was filed. If the year was not disclosed, we report the range of years covered by our public records requests. In a few cases, a start date was provided instead of a filing date. In those cases, we use the start date instead.
Fewer than 10% of records from the University of Florida and fewer than 1% of records from the University of Texas system were removed because they did not contain enough information.
ProPublica obtained additional financial disclosures and conflict of interest forms that we have not yet digitized and added to the database. You can download those disclosures in the ProPublica Data Store.